Evidence map›Paper›PMID 40133514›Full record

ArticleJournal of neurology2025

Exploring autoantigens in autoimmune limbic encephalitis using phage immunoprecipitation sequencing.

Haidara Kherbek, Naveen K Paramasivan, Surendra Dasari, Carley Karsten, Smathorn Thakolwiboon, Michael Gilligan, Andrew M Knight, Reghann G LaFrance-Corey, Vaniolky Losada, Andrew McKeon and 4 more

Abstract read
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Haidara KherbekDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
Naveen K ParamasivanDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
Surendra DasariDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
Carley KarstenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Smathorn ThakolwiboonDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
Michael GilliganDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Andrew M KnightDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Reghann G LaFrance-CoreyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Vaniolky LosadaFlorida State University College of Medicine, Tallahassee, FL, USA.
Andrew McKeonDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
Sean J PittockDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
Anastasia ZekeridouDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA.
John R MillsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Divyanshu DubeyDepartment of Neurology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, USA. dubey.divyanshu@mayo.edu.ORCID http://orcid.org/0000-0001-6865-9045

Funding

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of DiseaseU01NS120901 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stacey Lynn Clardy · 2021 to 2026
$19.6M
Seronegative Autoimmune Encephalopathies: Biomarker Discovery, Validation & Deep PhenotypingR01NS126227 · NINDS · MAYO CLINIC ROCHESTER · PI Andrew McKeon · 2022 to 2026
$1.9M
NINDS NIH HHS R01 NS126227NINDS NIH HHS U01 NS120901
6 · The paper itself

Abstract

objectivesTo describe the use of high-throughput whole-human proteome phage immunoprecipitation sequencing (PhIP-Seq) in identifying potential antigens for antibody-negative autoimmune limbic encephalitis (ALE).

methodsWe used PhIP-Seq to analyze cerebrospinal fluid (CSF) from patients with antibody-negative ALE evaluated in our lab with detailed clinical records available (2008-2023). Identified autoantigens were validated using recombinant protein-based assay.

resultsOf the 18 CSF samples from patients with ALE, 1 sample showed neuronal PAS domain protein 4 (NPAS4) as the putative autoantigen with the highest enrichment score. Patient presented with cognitive decline, gait dysfunction and unique MRI brain findings revealing asymmetric involvement of the medial temporal lobes with extension to the insular cortex and anterior temporal lobes. No malignancy was detected, and although the patient was initiated on immunotherapy, follow-up evaluation was limited. Another sample with very similar clinical and MRI brain findings, who developed ALE following COVID-19 infection, was referred for evaluation for neural-specific autoantibodies, and PhIP-Seq identified NPAS4 as the putative autoantigen. In both these samples, NPAS4-IgG was confirmed by cell-based assay (CBA) and enzyme-linked immunosorbent assay (ELISA). To assess the specificity of the NPAS4 autoantigen, a large cohort of disease (CSF, n = 49, serum, n = 220) and healthy controls (serum, n = 90) were tested by ELISA which were also negative. In addition, three samples had a high enrichment score for adenylate kinase 5 (AK5), an autoantigen associated with ALE. These patients also displayed a unique immunosignature that included AK5-IgG, which is distinct from NPAS4-IgG ALE or antibody-negative ALE. All three AK5-IgG seropositive cases presented with subacute memory loss, with MRI/PET brain florid showing medial temporal lobe involvement. No malignancy was detected in any of the three patients and immunotherapy led to improvement in one.

conclusionOur study demonstrates the utility of high-throughput PhIP-Seq in identifying potential autoantigens in antibody-negative ALE. The identification of NPAS4 as a putative antigen and identification of additional AK5-IgG-positive cases, underscores the potential of PhIP-Seq as a powerful tool in autoimmune disease research.

Indexed as

AutoantigensAutoimmune DiseasesBasic Helix-Loop-Helix ProteinsLimbic EncephalitisAdultAgedAutoantibodiesCOVID-19FemaleHumansImmunoprecipitationMaleMiddle AgedAutoantibodiesAutoantigensBasic Helix-Loop-Helix ProteinsAdenylate kinase 5 (AK5)Autoimmune encephalitisCognitive dysfunctionLimbic encephalitisNeuronal PAS domain protein 4 (NPAS4)Phage immunoprecipitation sequencing (PhIP-seq)

Identifiers

PMID40133514
PMCPMC12476888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.